🇺🇸 FDA
Patent

US 10416163

Method and treatment of recurring endometrial cancer with an inhibitor of USP14

granted A61KA61K31/55

Quick answer

US patent 10416163 (Method and treatment of recurring endometrial cancer with an inhibitor of USP14) held by Regents of the University of Minnesota expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Regents of the University of Minnesota
Grant date
Tue Sep 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/55